China: Pharmaceutical Trademark Protection In China

Last Updated: 18 July 2016
Article by Yu Li

The rise in IP litigation involving pharmaceutical trademarks, generic drug names and commodity names suggests that rights holders would do well to develop a trademark strategy for their pharmaceutical products in line with other aspects of IP protection. This is all the more crucial given that registered trademarks benefit from 10 years of protection and unlimited renewals – unlike patents, they can essentially enjoy permanent protection.

Registering pharmaceutical trademarks

Article 12 of the Quality Standard for Pharmaceutical Commodities (Trial Implementation, 1984) states that pharmaceuticals should have registered trademarks. Further, Article 27 of the Provisions of Pharmaceutical Direction and Labels (2006) prohibits pharmaceutical directions and labels from using unregistered trademarks or unapproved commodity names.

Pharmaceutical manufacturers thus need to register a trademark for their products before they enter the market – consumers can then be encouraged to refer to products by the designated trademark right from the start. In the same way, foreign or international enterprises should ensure that they have a Chinese trademark in place before their products are launched on the Chinese market. Case law in this area provides a stark illustration of why such precautions are necessary.

Viagra loses out to official Chinese registration

Pfizer's VIAGRA mark (1130739) was approved for registration in Class 5 for human drugs and medical preparations in China on November 28 1997 and then renewed for two further 10-year terms. Wellman applied to register the mark '伟哥' (1911818) in Class 5 on June 2 1998, with registration granted on June 22 2002. Pfizer applied to register the mark '伟哥', but its application was refused. In *Pfizer Inc v Jiangsu Lianhuan Pharmaceutical Co, Ltd* ((2009) Min Shen Zi No 312) the plaintiff and defendant submitted evidence which clearly demonstrated that, between 1998 and 2003, at least 30 newspapers described '伟哥' as the Chinese translation of 'Viagra'. '伟哥' is also described as the Chinese translation of 'Viagra' in the China Food and Drug Administration's Urgent Notice Concerning the Detainment of Counterfeit '伟哥' Drugs (1999, No 72).

The administration replied to Wellman in Urgent Notice 2000/19 that '伟哥' and its English name 'Viagra' are not the recognised pharmaceutical generic or commodity names of Pfizer's Sildenafil. Pfizer's attorney specifically stated that the commodity name of Viagra is '万艾可', a trademark registration for which is owned by Pfizer in China. Further, Pfizer admitted at first instance that it never used the '伟哥' mark.

Based on this evidence and these facts, the Beijing First Intermediate Court and the Supreme People's Court held that the evidence presented could not prove that '伟哥' was Pfizer's unregistered mark for Viagra. As a result, Pfizer lost trademark rights in '伟哥'.

Non-registrability of pharmaceutical generic names

A pharmaceutical generic name is the statutory name of the pharmaceutical containing its ingredients or formulation, and cannot be registered as a trademark. Article 11 of the Trademark Law (2013) also prohibits the registration of a product's generic name as a trademark. According to Article 59 and based on these regulations, it is clear that a pharmaceutical generic name cannot enjoy trademark rights.

In *Kunming City Lv Hai Yun Dan Trading Co, Ltd v GMP, Kunming Jing Yi Yuan Trading Co, Ltd* (2011, Yun Gao Min San Zhong Zi No 4) the plaintiff and its affiliate company were granted approval to manufacture '舒泌通胶囊' (Shu Mi Tong capsules) on September 8 2000. The plaintiff registered the '舒泌通' mark (4662653) and logo in Class 5. The defendant had manufactured '舒泌通片' (Shu Mi Tong tablets) under the '健发' mark and logo since 2002.

It was found that '舒泌通胶囊' was recognised as a generic name in 2002 and that '舒泌通片' was recognised as generic name in 2009. Considering that '舒泌通' had been recognised as a generic name for Chinese drugs, the plaintiff's claims of trademark infringement and unfair competition were rejected by the court.

Conflicts between commodity names and trademarks

A pharmaceutical commodity name is approved by the pharmaceutical supervisory and administrative department and is usually designed to be straightforward and easy to remember. A pharmaceutical trademark, on the other hand, is a mark which can serve to identify the source of the goods. It can be made up of text, graphics, letters, numbers, three-dimensional marks, colour combinations and sounds, as well as combinations of these elements, including the pharmaceutical commodity.

Considering that these names are regulated separately by the Drug Administration Law and the Trademark Law respectively, it is little wonder that conflicts between trademarks and commodity names often bring rights holders before the courts.

In *Wang Liang v Wuhan Administration for Industry and Commerce*, Shanxi Ya Bao Pharmaceutical Group Co, Ltd applied to register '丁桂' (3248395) – a combination of the Chinese names for clove and cinnamon – in Class 5 for tablets, patches and ointments in 2002. The mark was approved for registration on November 21 2013.

Wuhan City San Chu Technology Development Co, Ltd used the marks '丁桂宝' and '丁桂姜' on its paediatric diarrhoea medicine, with the packaging carrying the letters 'TM' on the top right. The official reply sent by the Trademark Office to the relevant administration for industry and commerce (AIC) on January 7 2006 mentioned that '丁桂儿剂贴' is the commodity name of a traditional Chinese drug whose ingredients include cloves ('丁香') and cinnamon ('肉桂'). According to Chinese proprietary naming rules, compound traditional Chinese drugs can be named by condensing the names of the main ingredients. Thus while the trademark owner could not prevent others from using '丁桂' to describe drugs containing cloves and cinnamon, the use should be limited to explaining the drug's ingredients. In this case, '丁桂宝' and '丁桂姜' were marked with 'TM' – the use thus constituted trademark infringement. The case was selected as one of the Supreme People's Procuratorate's top 10 typical IP cases of 2013.

In *Jilin Province Northern Pharmaceutical Co, Ltd v Jilin Province Hu Mua Animal Health Products Co, Ltd* (2015, Chang Min San Chu Zi No 82), the plaintiff applied to register the trademark '感康' (1775614) on December 17 1998 for human drugs in Class 5, with approval granted on May 28 2002. The mark was designated as being well known by the AIC in 2007. '华牧感康' was the commodity name of the defendant's lincomycin hydrochloride injection, which was approved by Jilin Province's animal husbandry authority as an animal drug on July 1997. '华牧感康' appeared prominently on the packaging of the defendant's poultry medicine. The court finally judged that '华牧感康' and '感康' constituted similar marks, human drugs and animal drugs were similar goods and the behaviour of the defendants constituted trademark infringement.

In this case, the defendant's commodity name was registered before the application date of the plaintiff's trademark. However, the use of the commodity name was still recognised as trademark infringement by the court. According to Article 59.3 of the Trademark Law, where an identical or similar trademark with certain influence has been used for the same or similar goods by others before the application is filed, the exclusive rights holder may not prohibit the user of the aforesaid trademark from continuous use of such within the original scope. However, it may request that the user affix additional logos in order to distinguish between the products.

The following conditions apply in order to cite this provision to defend against a plaintiff's claims:

  • The use of the commodity name must be earlier than the application date of the trademark; and
  • The commodity name was famous.

The evidence submitted by the defendant was insufficient to prove that the commodity name had been used before the application date of the trademark at issue. It also failed to prove that the commodity name at issue enjoyed a significant reputation in China.

Conclusion

To succeed in the Chinese pharmaceutical market, an enterprise should establish its trademark registration strategy at the same time as it develops its new drugs so that the drugs are protected by registration before they launch. Applications should avoid using generic names to ensure that exclusive rights can be obtained. Finally, while it is possible to use a commodity name which is similar to a registered trademark, such use should be carefully limited. A commodity name should never be used as a trademark, to avoid a finding of infringement.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions